Skip to main content

Table 2 Stroke deficits as assessed by NIHSS

From: A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial

Patient

Baseline/D0

D1

D2

D3

D4

D7

D8

D42

1

6

2

3

2

4

0

0

NP

2

7

6

5

6

NP

5

5

3

3

9

6

3

NP

NP

3

3

1

4

4

2

NP

NP

NP

2

NP

1

5

5

4

NP

NP

NP

1

NP

0

6*

1

2

2

2

2

13

NP

NP

Median

6

4

   

2

  
  1. NP – Not performed. * - not included in median NIHSS
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us